Pulmonary nodule on x-ray: an algorithmic approach.
CASE 1 * George D is a 67-year-old patient who has never smoked and who has no history of malignancy. An x-ray of his ribs performed after a fall shows a 13-mm solitary nodule in his right upper lung.
CASE 2 * Cathy B is a healthy 80-year-old with no history of smoking. During a trip to the emergency department for chest pain, she had a computed tomography (CT) scan of her chest. While the chest pain was subsequently attributed to gastroesophageal reflux, the CT revealed a 9-mm part solid nodule that was 75% solid.
How should the physicians caring for each of these patients proceed with their care?
The widespread use of sensitive imaging techniques often leads to the incidental discovery of unrelated--but possibly significant--pulmonary findings. Pulmonary nodules are incidentally discovered on an estimated 0.09% to 0.2% of all chest x-rays, 13% of all chest CT angiograms, (1) 31% of all cardiac CTs performed for coronary calcium scoring, (2) and up to 50% of thin-section chest CT scans. (1)
The widespread implementation of the US Preventive Services Task Force recommendations on lung cancer screening has further expanded the number of patients in whom asymptomatic pulmonary nodules will be detected. As a result, family physicians (FPs) will frequently encounter this challenging clinical dilemma and will need to:
* assess the patient's risk profile
* address the patient's concerns about malignancy while eliciting his or her preference for management
* minimize the risks of surveillance testing
* minimize patient distress while ensuring compliance with a follow-up that may extend up to 4 years
* determine when it's appropriate to refer the patient to a pulmonologist and/or pulmonary nodule clinic or registry.
* Taking these steps, however, can be challenging. In interviews, 15 primary care clinicians who care for patients with pulmonary nodules expressed concerns about limitations in time, knowledge, and resources, as well as a fear about such patients "falling through the cracks." (3) Familiarity with current evidence-based guidelines such as those from the American College of Chest Physicians (ACCP) and knowledge of emerging data on the management of various types of nodules are imperative.
To that end, this review will fill in the information gaps and provide guidance on how best to communicate what is known about a particular type of nodule with the patient who has one. (See "What to say to improve joint decision-making" (4-7) at right.) But first, a word about terminology.
Solid vs subsolid pulmonary nodules
Solid pulmonary nodules. Traditionally, the term "solitary pulmonary nodule" has been used to describe a single, well-circumscribed, radiographic opacity that measures up to 3 cm in diameter and is completely surrounded by aerated lung. (1,8) The term "solitary" is now less useful because increasingly sensitive imaging techniques often reveal more than one nodule. In the absence of evidence of features that strongly suggest a benign etiology, these are now commonly referred to as indeterminate solid nodules.
* Subsolid nodules are pulmonary nodules that have unique characteristics and require separate guidelines for management. Subsolid nodules include pure ground glass nodules (GGNs) and part solid nodules. GGNs are focal nodular areas of increased lung attenuation through which normal parenchymal structures such as airways, vessels, and interlobular septa can be visualized. (1,8) Part solid nodules have a solid component. They are usually, but not necessarily, >50% ground glass in appearance.
* Lung masses. Focal pulmonary lesions >3 cm in diameter are called lung masses and are presumed to be malignant (bronchogenic carcinoma) unless proven otherwise. (1,8)
* The specific approach to evaluating and monitoring a pulmonary nodule varies depending on whether the nodule is solid or subsolid and other factors, including the nodule's size.
Monitoring solid nodules
Monitoring of an indeterminate solid nodule is largely determined by the patient's risk profile and the characteristics of the identified nodule. (1) Independent patient predictors of malignancy include older age, smoking status, and history of prior malignancy (>5 years ago). Less established predictors are the presence of moderate or severe obstructive lung disease and exposure to particulate or sulfur oxide-related pollution. (9)
Patients who have an indeterminate nodule identified on chest x-ray should undergo a chest CT scan, preferably with thin sections through the nodule to help characterize it. (1) Nodule characteristics that can help predict a patient's risk of malignancy include the size (>8 mm confers higher risk), malignant rate of growth, edge characteristics (spiculation or irregular edges), thickness of the wall of a cavitary pulmonary nodule ([greater than or equal to] 16 mm has a likelihood ratio [LR] 37.97 of malignancy), and the location of the nodule (upper or middle lobe [LR=1.2 to 1.6]). (10) A lack of growth over 2 years and a benign pattern of calcification eliminate the need for further evaluation.
* Validated tools to help guide decisionmaking. Although many physicians estimate pretest probability of malignancy intuitively, validated tools are readily available and can help in clinical decision-making. (11) One such tool is the Mayo model, which is available at http://reference.medscape.com/calculator/ solitary-pulmonary-nodule- risk. This model takes into account the patient's age, smoking status, history of cancer, and characteristics of the nodule.
Solid nodules >8 mm to 3 cm
For a patient with a solid nodule >8 mm to 3 cm, ACCP guidelines suggest that physicians estimate the pretest probability of malignancy qualitatively using their clinical judgment and/- or quantitatively by using a validated model, such as the Mayo model described above.
Based on the patient's probability of malignancy, management options include continued CT surveillance, positron emission tomography (PET) imaging, CT-guided needle lung biopsy, bronchoscopy with biopsy, or surgical wedge resection (algorithm 1). (1)
CT surveillance is recommended for individuals:
* with very low (<5%) probability of malignancy
* with low to moderate (5% to 30%) or moderate to high (31% to 65%) probability of malignancy with negative functional imaging (PET)
* with high probability of malignancy (>65%) when needle biopsy is nondiagnostic and the lesion is not hypermetabolic on PET scan.
Surveillance is also recommended when a fully informed patient prefers nonaggressive management. The intervals for serial CT in this population are at 3 to 6 months, 9 to 12 months, and 18 to 24 months.
In an individual with a solid indeterminate nodule with a high probability of malignancy (>65%), functional imaging should not be performed to characterize the nodule. It may, however, be performed for staging.
* Time for biopsy or resection? If a nodule shows evidence of malignant growth on serial imaging, nonsurgical biopsy (CT scan-guided transthoracic needle biopsy, bronchoscopy guided by fluoroscopy, endobronchial ultrasound, electromagnetic navigation bronchoscopy, or virtual bronchoscopy navigation) or surgical resection is recommended.
Nonsurgical biopsy is also recommended when the patient's pretest probability and imaging test results are discordant, when a benign diagnosis requires specific medical treatment, or if a fully informed patient desires proof of diagnosis prior to surgery.
Thoracoscopy with wedge resection is the gold standard for diagnosis of a malignant nodule. It is recommended:
* when the clinical probability of malignancy is high (>65%)
* when the nodule is intensely hypermetabolic by PET scan or positive by other functional imaging tests
* when nonsurgical biopsy is suggestive of malignancy
* when a fully informed patient prefers a definitive diagnostic procedure.
CASE 1 * The FP contacts Mr. D and advises that he get a chest CT to better characterize his pulmonary nodule. A thin-slice CT of the lung reveals that the 13-mm solid nodule in the right upper lobe has spiculated margins. According to the Mayo risk calculator, Mr. D is at moderate risk of malignancy (32.5%). Mr. D and his physician discuss the findings and possible management options, and Mr. D opts to have a PET scan. The FP gives Mr. D literature on pulmonary nodules and contact information for the provider team. A PET scan shows negative uptake. Mr. D and his physician discuss CT surveillance and nonsurgical biopsy. He opts for CT surveillance. The next CT is scheduled for 3 months.
Solid nodules [less than or equal to] 8 mm
Management of these lesions generally follows the consensus-based guidelines that were first published by the Fleischner Society and subsequently endorsed by the ACCP. (1) The 2 main determinants that guide management of nodules [less than or equal to] 8 mm are the patient's risk factors for cancer and nodule size (algorithm 2). (1) The Fleischner guidelines pertain only to patients older than age 35 with no current extra pulmonary malignancy or unexplained fevers. The ACCP guidelines, although similar, do not include these limitations. Patient risk factors include history of smoking, older age, and a history of malignancy. (1)
* Patients with no risk factors for malignancy. The frequency of surveillance CT is determined by the size of the nodule. Nodules [less than or equal to] 4 mm do not need to be followed. For nodules >4 mm to 6 mm, a repeat CT in 12 months is recommended with no follow-up if stable. For nodules >6 to <8 mm, repeat CT is recommended at 6 to 12 months, and again between 18 and 24 months if unchanged. (1)
* Patients with one or more risk factors for malignancy. Nodules [greater than or equal to] 4 mm should be reevaluated at 12 months in patients with one or more risk factors; no additional follow-up is needed if unchanged. For nodules >4 mm to 6 mm, CT should be repeated between 6 and 12 months and again between 18 and 24 months. Nodules >6 mm to <8 mm should be followed initially between 3 to 6 months, then between 9 and 12 months and again at 24 months if unchanged. (1)
Subsolid nodules require a different approach
Subsolid nodules have a high prevalence of premalignant and malignant disease (adenocarcinoma in situ, minimally invasive adenocarcinoma, and adenocarcinoma). Studies have reported subsolid nodule malignancy rates ranging from 20% to 75%. (11-15) This wide range may be a function of different nodule sizes or rates of biopsy. The prevalence increases even further in nodules with a part solid component.
These factors, plus challenges in measuring serial growth on CT and the uncertain prognosis of untreated premalignant disease, make it necessary to have separate guidelines for managing subsolid nodules. The Fleischner Society, National Comprehensive Cancer Network, and the American College of Radiology (LungRads) each have differing recommendations on the frequency of follow-up for different-sized subsolid nodules. Newer studies favor a more conservative approach. (16) Here we describe the current ACCP guidelines for managing subsolid nodules (ALGORITHM 3). (1)
* GGNs. In an individual with a pure GGN [less than or equal to] 5 mm in diameter, no further evaluation is recommended. In an individual with a pure GGN >5 mm in diameter, annual surveillance with chest CT for at least 3 years is recommended. (1)
* Part solid nodules. In an individual with a part solid nodule [less than or equal to] 8 mm, conduct CT surveillance at 3,12, and 24 months and then annually for an additional one to 3 years. In a patient with a part solid nodule >8 mm to 15 mm, repeat chest CT at 3 months followed by a PET scan, nonsurgical biopsy, and/or surgical resection if the nodule persists. A patient with a part solid nodule >15 mm should undergo a PET scan, nonsurgical biopsy, and/or surgical resection.
CASE 2 * Ms. G is seen in the office by her FP, and they discuss management options. A repeat CT is done in 3 months and shows a persistent, unchanged nodule. Ms. G opts for a transthoracic biopsy, which reveals adenocarcinoma. Following a PET scan, which shows no evidence of metastasis, curative surgical wedge resection is done.
* Multiple subsolid nodules. In a patient who has a dominant nodule and one or more additional nodules, each nodule should be evaluated individually, according to recommendations from the Fleischner Society (the ACCP currently does not have guidelines for managing multiple subsolid nodules). An individual with multiple GGNs that all measure [less than or equal to] 5 mm should receive CT exams at 2 and 4 years. (13) A patient with multiple GGNs that include at least one nodule >5 mm but no dominant nodule should undergo follow-up CT at 3 months and annual CT surveillance for at least 3 years. (13)
* Order a computed tomography chest scan, preferably with thin sections through the nodule, to help characterize an indeterminate pulmonary nodule identified on x-ray. (B)
* Estimate the pretest probability of malignancy for a patient with a pulmonary nodule using your clinical judgment and/or by using a validated model, (B)
Strength of recommendation (SOR)
(A) Good-quality patient-oriented evidence
(B) Inconsistent or limited-quality patient-oriented evidence
(C) Consensus, usual practice, opinion, disease-oriented evidence, case series
What to say to improve joint decision-making (4-7)
Diagnosis and follow-up of a pulmonary nodule takes an emotional toll on patients, who often have a poor sense of what the presence of a nodule signifies. When caring for a patient with a pulmonary nodule, it's essential to have an effective communication strategy to ensure that he or she is a well-informed partner in decision-making.
Specifically, you'll need to describe the type of nodule that the patient has, how fast it might grow and its malignancy potential, steps that will need to be taken, and the importance of smoking cessation (if the patient smokes).
Ask the patient about any concerns/fears he or she may have, and provide resources to reduce them. Emphasize shared decision-making and discuss the rationale for various management plans and the limitations of diagnostic tests. Do not minimize the issue; emphasize the need for, and importance of, prolonged follow-up--even for a patient who has a small, low-risk nodule.
Samina Yunus, MD, MPH, Cleveland Clinic, Family Medicine, 551 East Washington Street, Chagrin Fails, OH 44022; email@example.com.
(1.) Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e93S-el20S.
(2.) Burt JR, Iribarren C, Fair JM, et al; Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology (ADVANCE) Study. Incidental findings on cardiac multidetector row computed tomography among healthy older adults: prevalence and clinical correlates. Arch Intern Med. 2008;168:756-761.
(3.) Golden SE, Wiener RS, Sullivan D, et al. Primary care providers and a system problem: A qualitative study of clinicians caring for patients with incidental pulmonary nodules. Chest. 2015;148:1422-1429.
(4.) Sullivan DR, Golden SE, Ganzini L, et al. 'I still don't know diddly': a longitudinal qualitative study of patients' knowledge and distress while undergoing evaluation of incidental pulmonary nodules. NPJ Prim Care Respir Med. 2015;25:15028.
(5.) van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J. 2011;38:154-161.
(6.) Wiener RS, Gould MK, Woloshin S, et al. What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest. 2013;143:672-677.
(7.) Wiener RS, Gould MK, Woloshin S, et al. 'The thing is not knowing': patients' perspectives on surveillance of an indeterminate pulmonary nodule. Health Expect. 2015;18:355-365.
(8.) Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246: 697-722.
(9.) Pope CA 3rd, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 2002;287:1132-1141.
(10.) Winer-Muram HT. The solitary pulmonary nodule. Radiology. 2006;239:34-49.
(11.) Gould MK, Ananth L, Barnett PG; Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest. 2007;131:383-388.
(12.) Seidelman JL, Myers JL, Quint LE. Incidental, subsolid pulmonary nodules at CT: etiology and management. Cancer Imaging. 2013;13:365-373.
(13.) Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology. 2013;266:304-317.
(14.) Oh JY, Kwon SY, Yoon HI, et al. Clinical significance of a solitary ground-glass opacity (GGO) lesion of the lung detected by chest CT. Lung Cancer. 2007;55:67-73.
(15.) Park CM, Goo JM, Lee HJ, et al. Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up. Radiographics. 2007;27:391-408.
(16.) Heuvelmans MA, Oudkerk M. Management of subsolid pulmonary nodules in CT lung cancer screening. J Thorac Dis. 2015;7:1103-1106.
Samina Yunus, MD, MPH; Peter Mazzone, MD, MPH Cleveland Clinic, Family Medicine, Chagrin Falls, Ohio (Dr. Yunus); Cleveland Clinic, Pulmonary Medicine, Ohio (Dr. Mazzone)
Dr. Yunus reported no potential conflict of interest relevant to this article. Dr Mazzone has served as a consultant to Integrated Diagnostics, Oncimmune, and Genentech.
|Printer friendly Cite/link Email Feedback|
|Author:||Yunus, Samina; Mazzone, Peter|
|Publication:||Journal of Family Practice|
|Date:||Feb 1, 2016|
|Previous Article:||Personality disorders: a measured response: improving your understanding of these disorders will help you identify specific diagnoses, ensure...|
|Next Article:||Case report.|